Safety and tolerance of L. reuteri in HIV

A prospective, double blind, placebo-controlled study in which 39 HIV-positive subjects (including 2 women), aged 23–50, consumed L. reuteri ATCC 55730 in a daily dose of 10¹⁰ CFU, or placebo, for 21 days. No significant differences could be seen in any of the parameters monitored (analyses of blood, serum and urine) or in regard to tolerance of L. reuteri intake. Colonisation of L. reuteri in the active group was verified.

Conclusion: The daily consumption of L. reuteri at the dosage of 10¹⁰ CFU for 21 days was shown to be safe and without any side-effects for adults infected with HIV.

Reference

Safety and tolerance of Lactobacillus reuteri supplementation to a population infected with the Human Immunodeficiency Virus. Wolf BW, Wheeler KB, Ataya DG, Garleb KA. (1998) Food Chem Toxicol. 36:1085-1094.